


**Amendment to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-19. Cancelled

20. (NEW) A compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof:




wherein

$n_1$ ,  $n_2$ , and  $n_3$  represent an integer of 1;

$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ , and  $R_6$  each independently represent a hydrogen atom;

$A_1$  and  $A_2$  each independently represent a hydrogen atom, a substitutable monocyclic or polycyclic heteroaromatic ring, a partly saturated substitutable polycyclic heteroaromatic ring, a substitutable monocyclic or polycyclic aromatic ring, a partially saturated substitutable polycyclic aromatic ring, a substitutable heteroring, or a group represented by the following formula (2):



wherein

$\text{R}_7$ ,  $\text{R}_8$ ,  $\text{R}_9$ , and  $\text{R}_{10}$  each independently represent a hydrogen atom, a substitutable alkyl group having 1 to 15 carbon atoms, a substitutable alkenyl group having 2 to 15 carbon atoms, a substitutable alkynyl group having 2 to 15 carbon atoms, or a substitutable cyclic alkyl group having 3 to 15 carbon atoms;

W represents a phenyl group;

X represents  $\text{CH}_2$ ;

D represents a group represented by the following formula (6):



wherein

Q represents  $\text{NR}_{12}$ , wherein  $\text{R}_{12}$  represents  $-(\text{CH}_2)_m\text{COOR}_{36}$ , wherein m represents an integer of 1 or 2 and  $\text{R}_{36}$  represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms;

Y represents  $-(\text{CH}_2)_{m3}-$  wherein  $m3$  represents an integer of 0 to 6; and

B represents  $\text{NR}_{25}\text{R}_{26}$  wherein  $\text{R}_{25}$  and  $\text{R}_{26}$  each independently represent a

hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or a cyclic alkyl group having 3 to 6 carbon atoms.

21. (NEW) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein A<sub>1</sub> is an imidazole group and A<sub>2</sub> is an imidazole group or an imidazole group substituted with an alkyl group.

22. (NEW) A compound and a pharmacologically acceptable salt thereof according to claim 20, wherein R<sub>36</sub> represents a hydrogen atom or an ethyl group.

23. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein R<sub>25</sub> and R<sub>26</sub> represent an alkyl group having 1 to 6 carbon atoms.

24. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 20, wherein the compound is selected from the group consisting of:

3-[(4-dipropylamino-butyl)-(4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid,

[(4-dipropylamino-butyl)-(4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-acetic acid, and

[[4-(dipropyl-amino)-butyl]-(4-[[1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid ethyl ester.

25. (NEW) A medical composition, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof, according to claim 20.

26. (NEW) A CXCR4 antagonist, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

27. (NEW) An antiviral drug, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

28. (NEW) A rheumatic disease ameliorating agent based on a CXCR4 antagonism, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof, according to claim 20.

29. (NEW) A cancer metastatic disease ameliorating agent based on a CXCR4 antagonism, comprising as an active ingredient the compound, or the pharmacologically acceptable salt thereof according to claim 20.

30. (NEW) A method of treating a cancer metastatic disease comprising administering the compound or the pharmacologically acceptable salt thereof according to claim 20.

31. (NEW) A method of treating a rheumatic disease comprising administering the compound or the pharmacologically acceptable salt thereof according to claim 20.

32. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is 3-[(4-dipropylamino-butyl)-(4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-amino]-propionic acid.

33. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [(4-dipropylamino-butyl)-(4-[[[1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-amino]-acetic acid.

34. (NEW) A compound or a pharmacologically acceptable salt thereof according to claim 24, wherein the compound is [[4-(dipropyl-amino)-butyl)-(4-[[1H-

SAITOU et al. - Serial No. 10/591,722  
Amendment Under 37 C.F.R. 1.111 And Record of Telephonic Interview  
Attorney Docket: MOEG-P100

imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl]-benzyl)-  
amino]-acetic acid ethyl ester.